Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>To assess the efficacy and safety of polyethylene glycol loxenatide (PEX168), a new glucagon‐like peptide receptor agonist, as an add‐on to metformin therapy in Chinese patients with type 2 diabetes mellitus (T2DM).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and methods</h3><p>This was a multicenter, randomized, double‐blind, placebo‐controlled phase 3b trial. After metformin monotherapy (≥1500 mg/day) for ≥8 weeks, patients with uncontrolled T2DM [glycated hemoglobin (HbA1c) 7.0%–10.5%] from 44 sites were randomized (1:1:1) to metformin + placebo, metformin + PEX168 100 μg, and metformin + PEX168 200 μg. The core treatment period lasted for 24 weeks, followed by a 28‐week extension period. The primary endpoint was the change in HbA1c levels at week 24. The main secondary endpoint was the proportion of patients with HbA1c <7.0% at week 24.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The least‐square mean (standard error) change in HbA1c levels was significantly greater (P < 0.001 for superiority) in PEX168 groups [−1.16% (0.08%) and − 1.14% (0.08%) with 100 μg and 200 μg, respectively] than in the placebo group [0.35% (0.08%)]. The proportion of patients with HbA1c <7.0% at week 24 was significantly higher in the PEX168 100 μg (37.4%) and PEX168 200 μg (40.6%) groups than in the placebo group (16.8%, both P < 0.001). The gastrointestinal reactions were mild; the risks of hypoglycemia and weight gain did not increase. Anti‐PEX168 antibodies were noted in less than 2% of patients. No treatment‐emergent SAEs occurred.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The subcutaneous injection of PEX168 once a week can effectively, continuously, and safely improve HbA1c levels in patients with T2DM when combined with metformin.</p><p>This article is protected by copyright. All rights reserved.</p></section>

PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration

Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Polydextrose Alleviates Adipose Tissue Inflammation and Modulates the Gut Microbiota in High-Fat Diet-Fed Mice

[The Preliminary Investigation of GLP-1 Receptor Agonist on Liver Steatosis in Obese Mice].

Effect of Exendin-4 on Lipid Deposition in Skeletal Muscle of Diet-Induced Obese Mice and Its Underlying Mechanism

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

Exenatide Mitigates Inflammation and Hypoxia along with Improved Angiogenesis in Obese Fat Tissue.

Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial

Grape Seed Proanthocyanidins Reduced The Overweight Of C57bl/6j Mice Through Modulating Adipose Thermogenesis And Gut Microbiota

Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice

Sulfated Polysaccharides from Enteromorpha prolifera Attenuate Lipid Metabolism Disorders in Mice with High-fat Diet-induced Obesity via an AMPK-dependent Pathway

Ginsenoside Rb1, salvianolic acid B and their combination modulate gut microbiota and improve glucolipid metabolism in high-fat diet induced obese mice

Diet-Induced Adipose Tissue Inflammation and Hypoxia Are Reversed by GLP-1 Potentially Via Improved Microcirculation

Bone marrow mesenchymal stem cell-derived exosomes reduce insulin resistance and obesity in mice via the PI3K/AKT signaling pathway

Exendin-4 Improves Fat Metabolism of Brown Adipose Tissue in High-Fat Diet-Induced Obese C57BL/6J Mice

Sulfated Polysaccharides from Enteromorpha Prolifera Attenuate Lipid Metabolism Disorders in Mice with Obesity Induced by a High-Fat Diet Via a Pathway Dependent on AMP-Activated Protein Kinase.

Emodin Improves Lipid and Glucose Metabolism in High Fat Diet-Induced Obese Mice Through Regulating SREBP Pathway.

Blueberry Polyphenols Extract As a Potential Prebiotic with Anti-Obesity Effects on C57BL/6 J Mice by Modulating the Gut Microbiota.

A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice

Therapeutic effect and mechanism of polysaccharides from Anoectochilus Roxburghii (Wall.) Lindl. in diet-induced obesity